Position in DATURA: WP4 Biological investigations
Job title: Head of Pharmaco-Toxicology Lab
Home Institution: Assistance Publique Hopitaux de Paris (AP-HP) Hôpital Bichat, France
ResearchGate link
E-mail: gilles.peytavin@aphp.fr
Dr Gilles Peytavin is a clinical pharmacologist, trained in infectious diseases, currently the Head of the Pharmacology-Toxicology Department of the Bichat-Claude Bernard University Hospital (Paris, France). His main scientific interest focus on HIV infection and related diseases, particularly in coinfections such as tuberculosis, viral hepatitis and opportunistic infections. Since more than 20 years, he is an expert of the French National Research Agency on AIDS and Viral Hepatitis (ANRS). He also takes part in the scientific committee of the International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. He has a lot of collaborations with internationally famous French physician specialised in infectious diseases, through original clinical studies conducted in France, Africa or Caribbean settings.
- Experience in HIV infection
Since the end of 90’s, Dr Peytavin developed in his lab the Therapeutic Drug Monitoring (TDM) of antiretroviral drugs (ARV) by determining their concentrations in different biological matrix (blood, plasma, hair, seminal, CSF, genital tissue, etc.) in routine as in clinical studies, for adherence difficulties, drug-drug interactions, pharmacokinetic (PK) in pregnancy, eonates, PK-PD relationships (virological failure or intolerance), etc. He follows more than 20,000 HIV-infected patients in TDM each year and participates in 10 different expert advice committees monthly in Paris. He has contributed to write more than 300 publications cited in Medline related to the HIV topics.
- Clinical research expertise
As pharmacological investigator of more than 100 clinical trials, Dr Peytavin has a large experience in clinical research. He is member of several scientific groups in ANRS called “Actions Coordonnées” (AC 43 – North & South HIV and Hepatitis Virology Research Group; AC43 – Resistance group; AC 44 – HIV Clinical Research) and now, is the scientific co-responsible of the Pharmacological Group of the AC43. Based on his expertise in clinical and pharmacological research in international collaborations, his involvement through antituberculosis and ARV drugs measurements will largely benefit to the DATURA clinical trial.
- Expertise in managing HIV program in resource limited settings
Since 2005, Dr Peytavin has developed the determination of indinavir plasma concentrations on dried blood spots (DBS) in HIV-infected African patients in collaboration with the team of Pr C Katlama (Pitié Salpêtrière Hospital, Paris, France) and the team of infectious diseases in Bamako (Cesac, Mali). In 2011, he has conducted, as a pharmacological investigator, a large study to determine the rate of viral success in 218 HIV-infected patients in Niamey (Niger) on first-line ARV therapy to assess the performance of DBS sampling for plasma HIV-RNA measurement, genotypic resistance and ARV concentration determinations.
DBS specimens have been shown to be a viable alternative to plasma specimens for TDM in HIV-1 infection patients and are more manageable in resource limited settings because they require minimal training to prepare, are stable at ambient temperature for several weeks, are deemed non-hazardous once they are dried, and can be shipped via regular mail or courier services to